How this variant relates to the sphingomyelin pathway is unclear and requires further investigation, particularly given that there are many variants that affect sphingomyelin levels and have no identified impact on NAFLD, for example, variants in sphingosine-1-phosphate phosphatase 1 (SGPP1) (35). Here, SGPP1 is linked to metabolic dysfunction-associated steatotic liver disease.